【正文】 al. Blood recirculation in temporary central catheters for acute hemodialysis. Clin Nephrol. May 1996。45(5):315319.14. Canaud B, Chenine L, Henriet D, et al. Optimal management of central venous catheters for hemodialysis. Contrib Nephrol. 2008。161(3947.15. Kellum JA, Mehta RL, Angus DC, et al. The first international consensus conference on continuous renal replacement therapy. Kidney Int. Nov 2002。62(5):18551863.16. Thomas CM, Zhang J, Lim TH, et al. Concentration of heparinlocking solution and risk of central venous hemodialysis catheter malfunction. Asaio J. JulAug 2007。53(4):485488.17. Aucella F, Di Paolo S, Gesualdo L. Dialysate and replacement fluid position for CRRT. Contrib Nephrol. 2007。156(287296.18. Maccariello E, Rocha E, Dalboni MA, et al. Customized bicarbonate buffered dialysate and replacement solutions for continuous renal replacement therapies: effect of crystallization on the measured levels of electrolytes and buffer. Artif Organs. Nov 2001。25(11):870875.19. Barenbrock M, Hausberg M, Matzkies F, et al. Effects of bicarbonate and lactatebuffered replacement fluids on cardiovascular oute in CVVH patients. Kidney Int. Oct 2000。58(4):17511757.20. Heering P, Ivens K, Thumer O, et al. The use of different buffers during continuous hemofiltration in critically ill patients with acute renal failure. Intensive Care Med. Nov 1999。25(11):12441251.21. Palsson R, Laliberte KA, Niles JL. Choice of replacement solution and anticoagulant in continuous venovenous hemofiltration. Clin Nephrol. Jan 2006。65(1):3442.22. Morgera S, Haase M, Rocktaschel J, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant. Dec 2003。18(12):25702576.23. Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med. Aug 2006。34(8):20992104.24. Haase M, Silvester W, Uchino S, et al. A pilot study of highadsorption hemofiltration in human septic shock. Int J Artif Organs. Feb 2007。30(2):108117.25. Nakada TA, Oda S, Matsuda K, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med. MayJun 2008。14(56):257263.26. Hirasawa H, Oda S, Matsuda K. Continuous hemodiafiltration with cytokineadsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol. 2007。156(365370.27. Opatrny K, Jr., Polanska K, Krouzecky A, et al. The effect of heparin rinse on the biopatibility of continuous venovenous hemodiafiltration. Int J Artif Organs. Jun 2002。25(6):520528.28. Davies H, Leslie G. Maintaining the CRRT circuit: nonanticoagulant alternatives. Aust Crit Care. Nov 2006。19(4):133138.29. Ramesh Prasad GV, Palevsky PM, Burr R, et al. Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clin Nephrol. Jan 2000。53(1):5560.30. van der Voort PH, Gerritsen RT, Kuiper MA, et al. Filter run time in CVVH: pre versus postdilution and nadroparin versus regional heparinprotamine anticoagulation. Blood Purif. 2005。23(3):175180.31. Uchino S, Fealy N, Baldwin I, et al. Predilution vs. postdilution during continuous venovenous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract. 2003。94(4):c9498.32. de Pont AC, Bouman CS, Bakhtiari K, et al. Predilution versus postdilution during continuous venovenous hemofiltration: a parison of circuit thrombogenesis. Asaio J. JulAug 2006。52(4):416422.33. Shulman RI, Singer M, Rock J. Continuous renal replacement therapy. Keeping the circuit open: lessons from the lab. Blood Purif. 2002。20(3):275281.34. Singer M, McNally T, Screaton G, et al. Heparin clearance during continuous venovenous haemofiltration. Intensive Care Med. 1994。20(3):212215.35. Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. Feb 2004。30(2):260265.36. Hirsh J, Raschke R. Heparin and lowmolecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. Sep 2004。126(3 Suppl):188S203S.37. Bagshaw SM, Laupland KB, Boiteau PJ, et al. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care. Jun 2005。20(2):155161.38. Oudemansvan Straaten HM, Wester JP, de Pont AC, et al. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. Feb 2006。32(2):188202.39. Biancofiore G, Esposito M, Bindi L, et al. Regional filter heparinization for continuous venovenous hemofiltration in liver transplant recipients. Minerva Anestesiol. Jun 2003。69(6):527534。 534528.40. Fealy N, Baldwin I, Johnstone M, et al. A pilot randomized controlled crossover study paring regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs. Apr 2007。30(4):301307.41. Reeves JH, Cumming AR, Gallagher L, et al. A controlled trial of lowmolecularweight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med. Oct 1999。27(10):22242228.42. Abramson S, Niles JL. Anticoagulation in continuous renal replacement therapy. Curr Opin Nephrol Hypertens. Nov 1999。8(6):701707.43. KozekLangenecker SA, Kettner SC, Oismueller C, et al. Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration. Crit Care Med. Jul 1998。26(7):12081212.44. Birnbaum J, Spies CD, Klotz E, et al. Iloprost for additional anticoagulation in c